N
BCAB icon

Nuveen’s BioAtla BCAB Stock Holding History

Nuveen’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,557
Closed -$612K – 3338
2024
Q1 		$612K Hold
3,557
– – ﹤0.01% 2903
2023
Q4 		$438K Buy
3,557
+120
+3% +$10.4K ﹤0.01% 3048
2023
Q3 		$292K Sell
3,437
-1,150
-25% -$147K ﹤0.01% 2972
2023
Q2 		$688K Buy
+4,587
New +$789K ﹤0.01% 2824
2022
Q2 		– Sell
-2,095
Closed -$572K – 3258
2022
Q1 		$572K Buy
2,095
+1,051
+101% +$440K ﹤0.01% 2975
2021
Q4 		$1.02M Sell
1,044
-237
-19% -$303K ﹤0.01% 2853
2021
Q3 		$1.89M Buy
1,281
+442
+53% +$861K ﹤0.01% 2695
2021
Q2 		$1.78M Sell
839
-47
-5% -$106K ﹤0.01% 2767
2021
Q1 		$2.25M Buy
+886
New +$2.27M ﹤0.01% 2561

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
SAM
Scion Asset Management Saratoga, California $1.38B AUM 43.96% 1-Year Est. Return

Nuveen's BCAB Position: Q2 2024 in Review

Nuveen sold out of BioAtla (BCAB) in Q2 2024, closing a stake of 3,557 shares — an estimated $612K sold.

Nuveen first reported a position in BCAB in Q1 2021 and held it in 9 quarters. The position peaked at $2.25M in Q1 2021. 80 funds tracked by Wall St. Rank hold BCAB as of Q2 2024.

  • Nuveen reported no remaining BioAtla position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 3,557 BioAtla shares in Q2 2024, an estimated $612K.
  • Nuveen first reported a position in BioAtla in Q1 2021 and held it in 9 quarters.
  • Nuveen's BioAtla position peaked at $2.25M in Q1 2021.
  • 80 funds tracked by Wall St. Rank held BioAtla as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.